Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
1.2Direct coupling of pharmacophores
What ifWhat if a single carbon–carbon bond joins the two pharmacophores directly?
Claim language“a linker, covalently bound to the primary pharmacophore”
Peripheral attachment atoms on rigid primary and secondary groups set the separation between their binding surfaces. Rotation about the direct bond lets the secondary group sample orientations at the entrance to the orthosteric pocket.
1.2Nitrile contact at the terminus
What ifWhat if a directly attached cyano group supplies the polar contact at R6?
The nitrile nitrogen acts as a hydrogen-bond acceptor for a pocket donor or an ordered water molecule. The linear cyano group gives the contact a fixed direction relative to its attachment bond.
1.2Cyclic sulfonamide at the terminus
What ifWhat if R5 and R6 form a six-membered cyclic sulfonamide?
Claim language“5-, 6-, or 7-membered cyclic amide, cyclic carbamate, or cyclic urea”
The ring constrains the orientation of the terminal group. Its tetrahedral sulfur projects two sulfonyl oxygens that act as hydrogen-bond acceptors.
1.3Competitive blockade at dopamine D3
What ifWhat if the compound reduces dopamine-driven D3 signaling through competitive antagonism?
The compound occupies the orthosteric site without activating the receptor and competes with dopamine for occupancy. In a D3-expressing cell assay, increasing antagonist concentrations shift the dopamine concentration–response curve to higher concentrations.
Section 2 · machine-generated
Variations
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Other field of use
Reference ligand for membrane assay calibration
A bitopic ligand with a primary pharmacophore, a covalent linker, and a secondary pharmacophore serves as a reference reagent for membrane assays. Separate wells contain membranes expressing the dopamine D3 or D2 receptor and a receptor-appropriate labeled tracer. Serial dilutions of the reference ligand displace the tracers, and fitted displacement curves track assay performance across membrane preparations.
Component substitution
Triazole spacer between the pharmacophores
A 1,4-disubstituted 1,2,3-triazole replaces the linker between the primary and secondary pharmacophores. The primary pharmacophore connects to triazole N1 through a methylene group, and the secondary pharmacophore connects to triazole C4 through a second methylene group. Cycloaddition joins the corresponding azidomethyl primary fragment and terminal alkyne secondary fragment, and paired receptor assays measure affinity and efficacy.
Parameter or scale variation
Six linker lengths for receptor profiling
A matched series contains six compounds with the same primary and secondary pharmacophores and the same attachment atoms. Linear saturated spacers contain 2, 3, 4, 5, 6, or 7 methylene units between those attachment atoms. Dopamine D3 and D2 binding and functional assays measure how spacer length changes affinity, receptor selectivity, and maximal response.
Combination with existing systems
Bitopic ligands in cell signaling assays
A cell-based cyclic AMP assay integrates the bitopic ligand with separate cell populations expressing dopamine D3 or D2 receptors. Each population receives a concentration series after adenylyl cyclase stimulation establishes an elevated cyclic AMP signal. A luminescent cyclic AMP sensor measures signal suppression, and a dopamine concentration series in the same cell population provides the reference maximal response.
Bitopic binding in receptor nanodiscs
Separate phospholipid nanodisc preparations contain purified dopamine D3 or D2 receptor, and matched empty nanodiscs provide a background control. The covalently linked bitopic ligand and a labeled orthosteric tracer equilibrate with each preparation. A tracer displacement assay measures receptor-associated binding in the defined lipid environment, and the empty nanodisc signal measures background association with the lipid and scaffold.
Automated or data-driven variant
Model guided selection of ligand variants
A database stores each ligand as a molecular structure and records its measured dopamine D3 and D2 affinities and functional responses. Software calculates molecular fingerprints and trains separate regression models for D3 affinity, the D2-to-D3 affinity ratio, and D3 maximal response relative to dopamine. An acquisition function ranks virtual combinations of the primary pharmacophore, linker, and secondary pharmacophore using predicted performance and uncertainty. Assay results for selected compounds update the models in the next selection cycle.
Specific version of a part
An ortho methoxy aromatic group
Ar is a 2-methoxyphenyl group with the methoxy substituent adjacent to the point of attachment. The phenyl ring supplies an aromatic surface, and the methoxy oxygen provides a hydrogen-bond acceptor.
Methoxyethyl group at R6
The L1 linker connects PP1 to SP1, with hydrogen at R5 and 2-methoxyethyl at R6. Two methylene units separate the attachment point from the ether oxygen, which acts as a hydrogen-bond acceptor.
D3 partial agonism in cells
A D3-selective version has a D3 binding affinity of 1 nM and a D2 binding affinity of 100 nM in matched competition assays. In a D3-mediated cyclic AMP assay, its maximal inhibition reaches 40% of the maximal dopamine response.
Section 3 · quoted from USPTO records
Other work
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
1.1PP is primary pharmacophore of formula PP1: wherein Ar is a substituted or unsubstituted aromatic or heteroaromatic substituent
and their pharmaceutically acceptable salts, wherein the symbol R1 represents C5-C12 cycloalkyl, aryl, heteroaryl or combinations thereof, wherein the cycloalkyl portions are monocyclic or polycyclic; the symbol P1 represents a primary pharmacophore selected from —NHC(O)NH—, —OC(O)NH—, —NHC(O)O—, —CH2C(O)NH—, —C(O)NH— and —NHC(O)—; the symbol P2 represents a secondary pharmacophore selected from —C(O)—, —CH(OH)—, —O(CH2CH2O)q—, —C(O)O—, —OC(O)—, —NHC(O)NH—, —OC(O)NH—, —NHC(O)
A · US 8,455,652 B2 · ¶ 11
wherein Ar is a heteroaryl which may be optionally substituted with 1, 2, or 3 substituents where each substituent independently is C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, C1-C6haloalkoxy, —OH, —COOH, amino, nitro, C2-C3alkanoyl group, mono- or di-C1-C3alkylamino, or halogen; specifically Ar is benzofuranyl, benzothienyl, imidazolyl, imidazo[1,2-a]pyridinyl, imidazo[2,1-b]thiazolyl, or indolyl; and more specifically Ar is benzofuranyl, benzothienyl, 4-ethyl-1H-imidazolyl, 4-
B · US 2020/0291000 A1 · ¶
1.2L is a linker, covalently bound to the primary pharmacophore, of formula L1, L2a, L2b, L2c, or L2d: and SP is a secondary pharmacophore, covalently bound to the linker, of formula SP1 when L is L1, or of formula SP2 when L is L2a, L2b, L2c, or L2d: wherein R5 is hydrogen or C1-8 alkyl, R6 is an amine, C1-8 alkyl amine, C1-8 alkyl, C1-8 alkoxy, a substituted or unsubstituted heterocycle, a substituted or unsubstituted aromatic, a substituted or unsubstituted heteroaromatic, or an ether-containing alkyl substituent, or R5 and R6 combine to form a 5-, 6-, or 7-membered cyclic amide, cyclic carbamate, or cyclic urea, and R21/22/29/30 is an amine, C1-8 alkyl amine, C1-8 alkyl, C1-8 alkoxy, a substituted or unsubstituted heterocycle, a substituted or unsubstituted aromatic, a substituted or unsubstituted heteroaromatic, or an ether-containing alkyl substituent
The right side of the primary pharmacophore is effectively divided into 4 segments: a spacer separating the primary and secondary pharmacophore (termed L1 in the present invention), the secondary pharmacophore (termed P2 in the present invention) and a tertiary pharmacophore (P3) flanked by a spacer (L2) and finally a terminating group Z (collectively provided with the tertiary pharmacophore as P3).
A · US 8,455,652 B2 · ¶ 67
1.3wherein the compound is a selective dopamine D3 receptor partial agonist.
The present disclosure is directed to novel dopamine D3 receptor selective antagonist/partial agonist compounds.
B · US 2020/0291000 A1 · ¶ 1
An empty cell means only that no passage was reproduced there.
Statements in these documents
Despite the activity associated with these inhibitors, there exists a need for compounds possessing similar or increased activities, with improved solubility to facilitate formulation and delivery.
A · US 8,455,652 B2 · ¶ 8
Surprisingly, the present invention provides such compounds along with methods for their use and compositions that contain them.
A · US 8,455,652 B2 · ¶ 9
The high degree of amino acid homology within the binding sites of the dopamine D2-like receptors, and especially between the D2 and D3 dopamine receptor subtypes, has provided a formidable challenge in the pursuit to discover dopamine D3-selective compounds that have drug-like properties.
B · US 2020/0291000 A1 · ¶ 3
Therefore, there is a well-recognized need in the art for highly D3-selective antagonists or partial agonists that are metabolically stable and have appropriate drug-like properties for potential translation to treat neuropsychiatric conditions including substance use disorders.
B · US 2020/0291000 A1 · ¶ 4
Cite aspatent.fyi, US 2026/0356809 A1, claim 1, first published 2026-11-20T07:31:16-05:00, https://patent.fyi/US20260356809/, SHA-256 f5d8ae79e86d07e0af0fa26f5caa9d63cccd37104f9494bb4bafd1d673ab1db7